The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)
Open accessAbstract
Background: Pemphigus encompasses a group of life‐threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first‐line treatment for moderate and severe pemphigus vulgaris in Europe and the United States. Objectives: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus. Results: The guidelines for the management of pemphigus were updated, and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organizations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion
Amagai, M., Klaus-Kovtun, V., & Stanley, J. R. (1991) · Cell · doi:10.1016/0092-8674(91)90360-b · Cited by 1,021
Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., Houivet, E., Calbo, S., Caillot, F., Golinski, M. L., Labeille, B., Picard-Dahan, C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30070-3 · Cited by 623
Self-citationSchmidt, E., Kasperkiewicz, M., & Joly, P. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31778-7 · Cited by 559
Self-citationKasperkiewicz, M., Ellebrecht, C. T., Takahashi, H., Yamagami, J., Zillikens, D., Payne, A. S., & Amagai, M. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.26 · Cited by 523
Self-citationA Single Cycle of Rituximab for the Treatment of Severe Pemphigus
Joly, P., Mouquet, H., Roujeau, J.-C., D'Incan, M., Gilbert, D., Jacquot, S., Gougeon, M.-L., Bedane, C., Muller, R., Dreno, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067752 · Cited by 466
Self-citationTreatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin
Ahmed, A. R., Spigelman, Z., Cavacini, L. A., & Posner, M. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062930 · Cited by 456
Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin
Stockman, J. A. (2008) · Yearbook of Pediatrics · doi:10.1016/s0084-3954(08)70301-4 · Cited by 404
The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels
Harman, K. E., Seed, P. T., Gratian, M. J., Bhogal, B. S., Challacombe, S. J., & Black, M. M. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04132.x · Cited by 274
A randomized double-blind trial of intravenous immunoglobulin for pemphigus
Amagai, M., Ikeda, S., Shimizu, H., Iizuka, H., Hanada, K., Aiba, S., Kaneko, F., Izaki, S., Tamaki, K., Ikezawa, Z., et al. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.09.052 · Cited by 255
Colliou, N., Picard, D., Caillot, F., Calbo, S., Le Corre, S., Lim, A., Lemercier, B., Le Mauff, B., Maho-Vaillant, M., Jacquot, S., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005166 · Cited by 249
Self-citationPrevalence and Age Distribution of Pemphigus and Pemphigoid Diseases in Germany
Hübner, F., Recke, A., Zillikens, D., Linder, R., & Schmidt, E. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.07.013 · Cited by 186
Self-citationInterventions for pemphigus vulgaris and pemphigus foliaceus
Martin, L. K., Agero, A. L., Werth, V., Villanueva, E., Segall, J., & Murrell, D. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006263.pub2 · Cited by 184
Self-citationMeggitt, S. J., Anstey, A. V., Mustapa, M. F. M., Reynolds, N. J., Wakelin, S. H., Tidman, M. J., Fuller, L. C., McLelland, J., Lear, J. T., Hughes, J. R., et al. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10575.x · Cited by 133
Schmidt, E., Goebeler, M., & Zillikens, D. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04744.x · Cited by 119
Self-citationKasperkiewicz, M., Shimanovich, I., Meier, M., Schumacher, N., Westermann, L., Kramer, J., Zillikens, D., & Schmidt, E. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10585.x · Cited by 86
Self-citationDevelopment of a Quality-of-Life Instrument for Autoimmune Bullous Disease
Sebaratnam, D. F., Hanna, A. M., Chee, S., et al. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.4972 · Cited by 84
Guslandi, M. (2013) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v4.i3.39 · Cited by 35
Cited by
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Unmet medical needs in chronic, non-communicable inflammatory skin diseases
Ujiie, H., Rosmarin, D., Schön, M. P., Ständer, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., Cole, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.875492 · Cited by 158
Ferretti, F., Cannatelli, R., Benucci, M., Carmagnola, S., Clementi, E., Danelli, P., Dilillo, D., Fiorina, P., Galli, M., Gallieni, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656362 · Cited by 39
Self-citationUnderstanding CD4+ T cells in autoimmune bullous diseases
Lee, A. Y., Kim, T., & Kim, J. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161927 · Cited by 13
“In that reason, steroid-sparing agents such as mycophenolate mofetil and azathioprine are often combined (7).”
Background
Metadata
- Authors
- Joly, P., Horvath, B., Patsatsi, Α., Uzun, S., Bech, R., Beissert, S., Bergman, R., Bernard, P., Borradori, L., Caproni, M., Caux, F., Cianchini, G., Daneshpazhooh, M., De, D., Dmochowski, M., Drenovska, K., Ehrchen, J., Feliciani, C., Goebeler, M., Groves, R., Guenther, C., Hofmann, S., Ioannides, D., Kowalewski, C., Ludwig, R., Lim, Y. L., Marinovic, B., Marzano, A. V., Mascaró, J. M., Mimouni, D., Murrell, D. F., Pincelli, C., Squarcioni, C. P., Sárdy, M., Setterfield, J., Sprecher, E., Vassileva, S., Wozniak, K., Yayli, S., Zambruno, G., Zillikens, D., Hertl, M., & Schmidt, E.
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2020-08-24
- Volume
- 34
- Issue
- 9
- Pages
- 1900-1913
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W3080818382
- Cited by
- 363
- References
- 17
- FWCI
- 23.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
